Saudi Arabia Human Insulin Market to be Dominated by Type I Diabetes through 2026
Increasing demand for biosimilar drugs and rising
geriatric population are driving the growth in Saudi Arabia Human Insulin
Market in the forecast period, 2022-2026.
According to TechSci Research report, “Saudi
Arabia Human Insulin Market By Indication (Type I Diabetes, Type II
Diabetes), By Route of Administration (Subcutaneous, Nasal, Intravenous,
Transdermal, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar,
Traditional), By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting,
Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled), By Products (Insulin Pens,
Insulin Pumps, Infusion System, Injection), By Region, Competition Forecast
& Opportunities, 2026”, the Saudi Arabia Human Insulin market is
expected to witness a growth of steady CAGR for the forecast period, 2022-2026.
Insulin controls the flow of carbohydrates and fat metabolism in the body.
Insulin is secreted in the pancreas, and it causes the fat and skeletal
tissues to absorb the blood from the glucose in the body. Changes in lifestyle
patterns and the prevalence of obesity and diabetic cases in the country are
expected to fuel the demand for effective diabetes treatment methods. The high
demand for Human Insulin is due to the growing needle anxiety and injuries
caused to take put blood from the body and the surge in the consumers'
awareness regarding the chances of occurrence of transmission of bloodborne pathogens.
However, stringent regulatory standards for the approval of novel
products and the higher cost of production may restrain the Saudi Arabia Human
Insulin market growth for the forecast period.
Browse over XX
market data Figures spread through 70 Pages
and an in-depth TOC on "Saudi Arabia Human Insulin Market"
https://www.techsciresearch.com/report/saudi-arabia-human-insulin-market/8096.html
The Saudi Arabia Human Insulin market is segmented on the basis of indication,
route of administration, type, onset time, products, competitional landscape,
and regional distribution.
On the basis of the indication, the Saudi Arabia Human Insulin market is
divided into type I diabetes and type II diabetes. The type I diabetes segment
is expected to dominate the market share for the forecast period, 2022-2026.
Patients suffering from Type I diabetes require the treatment of insulin
therapy, which focuses on leveling blood sugar levels along with proper diet,
lifestyle, and timely dosage of insulin to eliminate the chances of
complications.
On the basis of the type, the Saudi Arabia Human Insulin market is
divided into basal, bolus, pre-mixed, biosimilar, and traditional. The
biosimilar segment is expected to witness substantial growth in the next five
years. The rise in the expenditure capacity on diabetes treatment and
supportive government policies promoting the development of biosimilar drugs
with higher effects and lower side effects is expected to drive the demand for the
segment.
On the basis of the onset time, the Saudi Arabia Human Insulin market is
divided into rapid-acting, short-acting, intermediate-acting, long-acting,
ultra-long acting, pre-mixed, and inhaled. The short-acting insulin segment is
expected to hold the largest market share for the next five years. Short-acting
insulin is witnessing high demand due to its advantages, such as faster
absorption and onset action rate.
It mimics the physiological prandial insulin peak of people without
diabetes leading to lower postprandial glucose levels. Short-acting insulin
controls the glucose level in a more efficient way and helps in enhancing the
patient’s quality of life by allowing lesser restrictions on the choice of
meals.
On the basis of the products, the Saudi Arabia Human Insulin market is
divided into insulin pens, insulin pumps, infusion system, and injection. The
insulin pens segment is expected to witness the fastest incremental growth for
the next five years. The high focus of the market players on the development of
insulin pens and the presence of a huge population pool suffering from diabetes
are the contributing factors driving the demand for insulin pens in the next
five years.
The launch of novel insulin pens enlisted with attractive features to attract
the patients and the availability of medical reimbursements to avail the
healthcare services is further expected to accelerate the insulin pens market
demand in the country.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=8096
Customers can also request for 10% free customization on
this report.
“The rise in the
efforts made by the leading authorities to restructure the healthcare system
and privatize the public hospital along with the availability of insurance
coverage for both foreigners and citizens is expected to boost the Saudi Arabia
healthcare system. Adoption of advanced technologies and equipment to treat the
patients and the rising consumer awareness about the benefits of using novel
diabetic treatment methods is expected to propel the Saudi Arabia Human Insulin
market growth till 2026” said Mr. Karan Chechi, Research Director with TechSci
Research, a research based global management consulting firm.
“Saudi Arabia Human
Insulin Market By Indication (Type I Diabetes, Type II Diabetes), By Route of
Administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and
Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset
Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long
Acting, Pre-Mixed, Inhaled), By Products (Insulin Pens, Insulin Pumps, Infusion
System, Injection), By Region, Competition Forecast & Opportunities, 2026”, has evaluated the
future growth potential of Saudi Arabia Human Insulin market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers, challenges,
and opportunities in Saudi Arabia Human Insulin market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com/